The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Il'ina L.M.

Assotsiatsiia ginekologov-éndokrinologov, Moskva

Yureneva S.V.

Acad. V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, Moscow, Russia

Dubrovina A.V.

Acad. V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, Moscow, Russia

Jebzieva Z.H.

Federal State Budget Institution «Research Center for Obstetrics, Gynecology and Perinatology» Ministry of Healthcare of the Russia, Moscow, Russia, 117997

The influence of menopause on life of working women: the problem without necessary attention

Authors:

Il'ina L.M., Yureneva S.V., Dubrovina A.V., Jebzieva Z.H.

More about the authors

Journal: Russian Journal of Human Reproduction. 2016;22(1): 87‑94

DOI: 10.17116/repro201622187-94

Views: 2973

Downloaded: 44

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Il'ina LM, Yureneva SV, Dubrovina AV, Jebzieva ZH. The influence of menopause on life of working women: the problem without necessary attention. Russian Journal of Human Reproduction. 2016;22(1):87‑94. (In Russ.)
https://doi.org/10.17116/repro201622187-94

 
МСФ на ЯМ
Close metadata

Female life expectancy has increased recently. In spite of a negative influence of menopause on many aspects of life of working women this problem has not attracted the necessary attention of the researchers and only recently the attitude to that question has begun to change. The use of menopausal hormonal therapy (MHT) in low or ultra low dose is discussed.

Keywords:

postmenopause
menopausal hormone therapy
ultra-low-dose
low-dose
vasomotor symptoms

Authors:

Il'ina L.M.

Assotsiatsiia ginekologov-éndokrinologov, Moskva

Yureneva S.V.

Acad. V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, Moscow, Russia

Dubrovina A.V.

Acad. V.I. Kulakov National Medical Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia, Moscow, Russia

Jebzieva Z.H.

Federal State Budget Institution «Research Center for Obstetrics, Gynecology and Perinatology» Ministry of Healthcare of the Russia, Moscow, Russia, 117997

List of references:

  1. Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2010. Natl Vital Stat Rep 2013;61(4):1-118. PMID:24979972.
  2. Toossi M. Employment outlook: 2010—2020. Mon Labor Rev 2012;135:43-64. Available at: http://www.bls.gov/opub/mlr/2012/01/art3full.pdf.
  3. United States Department of Labor, Bureau of Labor Statistics. Women at work. 2011. Available at: http://www.bls.gov/cps/demographics.htm#women. Accessed December 7, 2014.
  4. United Kingdom Office of National Statistics, 2010. www.statistics.gov.uk/2. United States Joint Economic Congress, 2010. www.jec.senate.gov/public/
  5. Tilly J, O’Leary J, Russell G. (2013). Older Women Matter: Harnessing the Talents of Australia’s Older Female Workforce. Available at: http://dca.org.au/files/file/DCA%20Older%20Women%20Matter%20Exec%20Summary%20online.pdf.
  6. Федеральная служба государственной статистики. Трудовые ресурсы. Занятость и безработица в Российской Федерации в октябре 2015 г. (по итогам обследований населения по проблемам занятости). http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/wages/labour_force/
  7. Чазова И.Е., Сметник В.П., Балан В.Е., и др. Ведение женщин с сердечно-сосудистым риском в пери- и постменопаузе: консенсус российских кардиологов и гинекологов. Российский кардиологический журнал. 2008;4:61-78.
  8. Жаркова С.Л. Проблемы использования трудового потенциала лиц пожилого возраста на российском рынке труда. Вестник НГУ. Серия: Социально-экономические науки. 2009; 9(3):34-38.
  9. Burn KF, Ames D, Henderson VW, et al. The role of grandparenting in post-menopausal women's cognitive health: results from the Women's Healthy Ageing Project (WHAP). Menopause. 2014;21:1069-1074. doi: 10.1097/GME.0000000000000236.
  10. Whiteley J, Wagner A, Kopenhafer L, Dibonaventura M. The impact of the severity of vasomotor symptoms on health status, resource use and productivity. Menopause. 2013;20:518-524.  doi: 10.1097/GME.0b013e31827d38a5.
  11. Fenton A, Panay N. Menopause and the workplace. Climacteric. 2014;17:317-318.  doi: 10.3109/13697137.2014.932072.
  12. Kopenhager T, Guidozzi F. Working women and the menopause. Climacteric. 2015;18:372-375.  doi: 10.3109/13697137.2015.1020483.
  13. Freeman EW, Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric. 2007;10:197-214. doi: 10.1080/13697130601181486.
  14. Guidozzi F. Sleep and sleep disorders in the menopausal women.. Climacteric. 2013;16:214-219.  doi: 10.3109/13697137.2012.753873.
  15. Epperson CN, Sammel MD, Freeman EW. Menopause effects on verbal memory: findings from a longitudinal community cohort. J Clin Endocrinol Metab. 2013;98:3829-3838. doi: 10.1210/jc.2013-1808.
  16. Weber MT, Maki PM, McDermott MP. Cognition and mood in perimenopause: a systematic review and metaanalysis. J Steroid Biochem Mol Biol. 2014;142:90-98.  doi: 10.1016/j.jsbmb.2013.06.001.
  17. Mitchell ES, Woods NF. Cognitive symptoms during the menopausal transition and early postmenopause. Climacteric. 2011;14:252-261.  doi: 10.3109/13697137.2010.516848.
  18. Gold EB, Sternfeld B, Kelsey JL, et al. Relation of demographic and lifestyle factors to symptoms in a multi-racial/ethnic population of women 40-55 years of age. Am J Epidemiol. 2000;152:463-473.  doi: 10.1093/aje/152.5.463.
  19. Griffiths A, MacLennan SJ, Hassard J. Menopause and work: An electronic survey of employees' attitudes in the UK. Maturitas. 201376(2):155-159.  doi: 10.1016/j.maturitas.2013.07.005.
  20. Geukes M, van Aalst MP, Nauta MCE, Oosterhof H. The impact of menopausal symptoms on work ability. Menopause. 2012;19:278-282.  doi: 10.1097/gme.0b013e31822ddc97.
  21. Jack G, Bariola E, Riach K, Schnapper J, Pitts M. Work, women and the menopause: an Australian Exploratory Study. Climacteric. 2014;17(Suppl 2):34.
  22. Eriksson A-K, van den Donk M, Hilding A, et al. Work Stress, Sense of Coherence, and Risk of Type 2 Diabetes in a Prospective Study of Middle-Aged Swedish Men and Women. Diabetes Care. 2013;36:2683-2689. Published online 2013 Aug 13.  doi: 10.2337/dc12-1738.
  23. Epel ES, McEwen B, Seeman T, et al. Stress and body shape: stress-induced cortisol secretion is consistently greater among women with central fat. Psychosom Med. 2000;62:623-632.
  24. Lloyd C, Smith J, Weinger K. Stress and Diabetes: A Review of the Links. Diabetes Spectrum. 2005;18(2):121-127.  doi: 10.2337/diaspect.18.2.121.
  25. Sarrel P, Portman D, Lefebvre P, et al. Incremental direct and indirect costs of untreated vasomotor symptoms. Menopause. 2014;22(3):260-266.  doi: 10.1097/GME.0000000000000320.
  26. MacLennan AH, Broadbent JL, Lester S, et al. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004;4:CD002978. doi: 10.1002/14651858.CD002978.pub2.
  27. de Villiers TJ, Pines A , Panay N, et al, on behalf of the International Menopause Society. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric. 2013;16:316-337.  doi: 10.3109/13697137.2013.795683.
  28. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010;95(Suppl 1):1-66.  doi: 10.1210/jc.2009-2509.
  29. The 2012 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2012;19(3):257-271.  doi: 10.1097/gme.0b013e31824b970a.
  30. Stuenkel SA, Gass M LS, Manson JE, et al. A decade after the Women's Health Initiative—the experts do agree. J Clin Endocrinol Metab. 2012;97(8):2617-2618. doi: 10.1210/jc.2012-2403.
  31. Salpeter SR, Buckley NS, Liu H, Salpeter EE. The cost-effectiveness of hormone therapy in younger and older postmenopausal women. Am J Med. 2009;122:42-52.e2.  doi: 10.1016/j.amjmed.2008.07.026.
  32. Simon JA, Reape KZ. Understanding the menopausal experiences of professional women. Menopause. 2009;16(1):73-76.  doi: 10.1097/gme.0b013e31817b614a.
  33. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.  doi:10.1001/jama.288.3.321.
  34. Rossouw JE, Manson JE, Kaunitz AM , Anderson GL. Lessons learned from the Women’s Health Initiative trials of menopausal hormone therapy. Obstet Gynecol. 2013;121:172-176.  doi: http://10.1097/AOG.0b013e31827a08c8.
  35. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310:1353-1368. doi: 10.1001/jama.2013.278040.
  36. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt). 2006;15:35-44.
  37. Mikkola TS, Tuomikoski P, Lyytinen H, et al. Estradiol-based postmenopausal hormone therapy and risk of cardiovascular and all-cause mortality. Menopause. 2015;22(9):976-983.  doi: 10.1097/GME.0000000000000450.
  38. Lobo RA. The hope for KEEPS. Climacteric.2015;18:108-109.  doi: 10.3109/13697137.2015.1007428.
  39. Hodis HN, Mack WJ, Shoupe D, MD, et al. Methods and Baseline Cardiovascular Data From the Early Versus Late Intervention Trial With Estradiol Testing the Menopausal Hormone Timing Hypothesis. Menopause. 2015;22(4):391-401.  doi: 10.1097/GME.0000000000000343.
  40. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: Randomised trial. BMJ. 2012;345:e6409. doi: 10.1136/bmj.e6409.
  41. Boardman HM, Hartley L, Eisinga A, Main C, Roqué I, Figuls M, et al. Hormonetherapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015;3:CD002229. doi: 10.1002/14651858.CD002229.pub4.
  42. ACOG Committee opinion №556. Postmenopausal Estrogen Therapy: Route of Administration and Risk of Venous Thromboembolism. Obstet Gynecol. 2013;121:887-904.  doi: 10.1097/01.AOG.0000428645.90795.d9.
  43. Herber-Gast G-CM, Mishra GD. Early severe vasomotor menopausal symptoms are associated with diabetes. Menopause. 2014:21(8):21(8):855-860.  doi: 10.1097/GME.0000000000000171.
  44. Francoa OH, Mukaa T, Colpania V, et al. Vasomotor symptoms in women and cardiovascular risk markers: Systematic review and meta-analysis. Maturitas. 2015;81:353-361.  doi: 10.1016/j.maturitas.2015.04.016.
  45. Lambrinoudaki I, Augoulea A, Armeni E, et al. Menopausal symptoms are associated with subclinical atherosclerosis in healthy recently postmenopausal women. Climacteric. 2012;15:350-357.  doi: 10.3109/13697137.2011.618564.
  46. Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic Effects of Postmenopausal Hormone Therapy: The Heart and Estrogen/progestin Replacement Study. A Randomized, Double-Blind, Placebo-Controlled Trial. Ann Intern Med. 2003;138:1-9.  doi:10.7326/0003-4819-138-1-200301070-00005.
  47. Maki PM, Dumas J. Mechanisms of Action of Estrogen in the Brain: Insights from Human Neuroimaging and Psychopharmacologic Studies. Semin Reprod Med. 2009;27:250-259.  doi: 10.1055/s-0029-1216278.
  48. McEwen BS. Physiology and Neurobiology of Stress and Adaptation: Central Role of the Brain. Physiol Rev. 2007;87:873-904.  doi:10.1152/physrev.00041.2006.
  49. Gass MLS, Maki P, Shifren JL, et al. NAMS supports judicious use of systemic hormone therapy for women aged 65 years and older. Menopause. 2015;22(7):685-686.  doi: 10.1097/GME.0000000000000491.
  50. Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause. 2014;21(9):924-932.  doi: 10.1097/GME.0000000000000196.
  51. Avis NE, Crawford SL, Greendale G, et al; the Study of Women’s Health Across the Nation (SWAN). Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531-539.  doi: 10.1001/jamainternmed.2014.8063.
  52. Gartoulla P, Worsley R, Bell RJ, Davis SR. Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 years [published online ahead of print February 20, 2015]. Menopause. 2015. doi: 10.1097/gme.0000000000000383.
  53. Kaunitz AM, Manson JE. EDITORIAL. Failure to treat menopausal symptoms: a disconnect between clinical practice and scientific data. Menopause. 2015;22(7):687-688.  doi: 10.1097/GME.0000000000000457.
  54. ACOG Committee Opinion on Gynecologic Practice № 565. Hormone Therapy and Heart Disease. Obstet Gynecol. 2013;121(6):1407-1410. doi: 10.1097/01.AOG.0000431053.33593.2d.
  55. Panay N, Hamoda H, Arya R, et al. The 2013 British Menopause Society &Women’s Heath Concern recommendations on hormone replacement therapy. Menopause Int. 2013;19:59-68. doi: 10.1177/1754045313489645.
  56. Notelovitz M, Lenihan JP, McDermott M, et al. Initial 17ß-estradiol dose for treating vasomotor symptoms. Obstet Gynecol. 2000;95:726-731.  doi: 10.1016/S0029-7844(99)00643-2.
  57. Practice Bulletin ACOG No. 141: Management of Menopausal Symptoms. Obstet Gynecol. 2014;123:202-216.  doi: 10.1097/01.AOG.0000441353.20693.78.
  58. Archer DF, Schmelter Th, Schaefers M, et al. A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women. Menopause. 2014; 21(3):227-235. doi: 10.1097/GME.0b013e31829c1431.
  59. Genazzani AR, Schmelter T, Schaefers M, Gerlinger C, Gude K. One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women. Climacteric. 2013;16:490-498.  doi: 10.3109/13697137.2013.783797.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.